HSBC also cut its price target to $850 from $1,070. The stock is currently trading around $989.
Eli Lilly receives its only sell rating from HSBC, which cites smaller market for weight-loss drugs
HSBC also cut its price target to $850 from $1,070. The stock is currently trading around $989.